A Longs shot for Walgreen and CVS
The rivalry between the nation’s two leading drugstore chains –- Walgreen and CVS –- is heating up as they battle for one of the last big prizes in the chain drugstore industry: Longs Drug Stores.
With some 520 stores in Hawaii, California, Nevada, and Arizona, Longs Drug Stores is indeed desirable.
Last month CVS bid $71.50 per share (about $2.9 billion) to acquire the chain, citing its valuable store locations in fast-growing markets. Indeed, in its press release CVS noted that it had “conservatively valued the store locations alone at more than $1 billion,” adding that Longs’ stores were situated in markets where “commercial real estate values are among the highest in the country.”
So it should come as no surprise that after boasting about Longs’ real estate riches, CVS met with rejection from Longs’ shareholders on the basis that its offer undervalues the chain’s property assets. Advisory Research Inc., which holds about 9% of Longs’ stock, has said it will not tender its shares to CVS at the $71.50-per-share price. The New York hedge fund Pershing Square Capital Management, led by the activist shareholder William Ackman, also rejected the CVS offer as too low and called for a competitive sale.
Enter Walgreen, which on Friday made an unsolicited bid of $75 per share for Longs. Yesterday, Longs rejected Walgreen’s sweeter offer and said its board continues to recommend the CVS deal to shareholders. (CVS has extended the expiration date for the tender offer to October 15 from September 15.) CEO Tom Ryan has said CVS is “not moving” on its price.
It’s hard to imagine that Walgreen will walk away or that Longs’ investors will settle for less than $75 per share. (Earlier this week Longs’ shares topped $76 per share, an all-time high.) Walgreen has said it’s prepared to take its offer directly to Longs’ shareholders, and it has offered to pay the $115 million termination fee if the Longs/CVS deal falls through.
While Walgreen has historically steered clear of big acquisitions, preferring to build its own stores, Longs is too luscious to let slip away. Longs’ presence in key West Coast markets, plus the fact that if CVS prevails its store count will surpass Walgreen’s, make winning Longs’ hand imperative.
Walgreen has deep pockets, possibly deeper than CVS’s following its $26.5 billion purchase of pharmacy benefits manager Caremark just last year. Longs’ savvy shareholders are itching for a bidding war and have raised the possibility of other potential bidders, including real estate players and retail giant Wal-Mart Stores. My guess is that ultimately CVS will have to raise its $71.50 offer to have a chance of landing Longs.











